However, in terms of pathogenicity (Fig. 1b), only a few BRCA1/2 mutations in cutaneous melanoma (8/48, 16.7%) and tumors located in the head and neck (5/27, 18.5%) and CNS (1/7, 12.5%) were deleterious. Here, BRCA1 is linked to cutaneous melanoma.